NCT02743819View on ClinicalTrials.gov

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 28, 2016

Primary Completion Date

June 1, 2022

Study Completion Date

June 30, 2026

Conditions
Melanoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab given every 3 weeks (200 mg) by IV infusion.

DRUG

Ipilimumab

Ipilimumab given every 3 weeks (200 mg) by IV infusion for total of 4 doses.

Trial Locations (10)

23298

Virginia Commonwealth University/ Massey Cancer Center, Richmond

33140

Mount Sinai Medical Center of Florida, Miami Beach

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

36604

University of South Alabama, Mobile

46804

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

60068

Oncology Specialists S.C., Park Ridge

60201

NorthShore University HealthSystem, Evanston

60637

University of Chicago, Chicago

61615

Illinois Cancer Care, Peoria

62526

Decatur Memorial Hospital, Decatur

All Listed Sponsors
lead

University of Chicago

OTHER